Dacarbazine (DTIC) is the treatment of choice for metastatic melanoma, but its response in patients remains very poor. Ceramide has been shown to be a death effector and to play an important role in regulating cancer cell growth upon chemotherapy. Among ceramidases, the enzymes that catabolize ceramide, acid ceramidase (aCDase) has been implicated in cancer progression. Here we show that DTIC elicits a time and dosedependent decrease of aCDase activity and an increase of intracellular ceramide levels in human A375 melanoma cells. The loss of enzyme activity occurred as a consequence of ROS-dependent activation of cathepsin Bmediated degradation of aCDase. These events preceded autophagic features and loss of cell viability. Downregulation of acid but not neutral or alkaline ceramidase 2 resulted in elevated levels of ceramide and sensitization to the toxic effects of DTIC. Conversely, inducible overexpression of acid but not neutral ceramidase reduced ceramide levels and conferred resistance to DTIC. In conclusion, we report that increased levels of ceramide, due to enhanced degradation of aCDase, are in part responsible for the cell death effects of DTIC. These results suggest that downregulation of aCDase alone or in combination with DTIC may represent a useful tool in the treatment of metastatic melanoma.
Dacarbazine (DTIC) is the treatment of choice for metastatic melanoma, but its response in patients remains very poor. Ceramide has been shown to be a death effector and to play an important role in regulating cancer cell growth upon chemotherapy. Among ceramidases, the enzymes that catabolize ceramide, acid ceramidase (aCDase) has been implicated in cancer progression. Here we show that DTIC elicits a time and dosedependent decrease of aCDase activity and an increase of intracellular ceramide levels in human A375 melanoma cells. The loss of enzyme activity occurred as a consequence of ROS-dependent activation of cathepsin Bmediated degradation of aCDase. These events preceded autophagic features and loss of cell viability. Downregulation of acid but not neutral or alkaline ceramidase 2 resulted in elevated levels of ceramide and sensitization to the toxic effects of DTIC. Conversely, inducible overexpression of acid but not neutral ceramidase reduced ceramide levels and conferred resistance to DTIC. In conclusion, we report that increased levels of ceramide, due to enhanced degradation of aCDase, are in part responsible for the cell death effects of DTIC. These results suggest that downregulation of aCDase alone or in combination with DTIC may represent a useful tool in the treatment of metastatic melanoma.
Melanoma is the most deadly form of skin cancer that originates from melanocytes, the melanin-producing cells located in the basal layer of the epidermis. The incidence of melanoma has been increasing over decades, especially among fair-skinned people (1) . Earlystage melanoma can be readily cured by surgical excision of the primary lesion, but advanced melanoma, often a metastatic disease, has a poor median survival, ranging from 2 to 8 months, with only 5% surviving more than 5 years (2) .
Metastatic melanoma is very resistant to many forms of traditional chemotherapy. To date, dacarbazine (DTIC) is considered to be the reference single agent for the management of advanced melanoma, with objective tumor responses in approximately 15-25% of patients. However, more than 95% of the responses are partial, with a 6-year median survival of 2% (3) . Temozolomide is an orally available DTIC analogue that has shown efficacy in the treatment of a variety of solid tumors, with the advantage of central nervous system penetration. Temozolomide and DTIC have demonstrated equal efficacy in terms of objective response rate and overall survival for patients with advanced metastatic melanoma (4) . Since the original approval of DTIC in 1975 for the treatment of metastatic melanoma, considerable effort has been expended in attempts to improve survival. However, treatments based on the combination of these agents with other cytotoxics or immunotherapy have not resulted in response rates of durable remission, enough to increase the median survival of the patients (3) .
Sphingolipids are a complex family of bioactive lipids that play important structural and second messenger roles (5) . Ceramide is the ! #! central molecule to both metabolism and signalling of sphingolipids. It has been implicated in several cellular processes like cell cycle arrest, apoptosis and cell senescence (6, 7) . Therefore, dysregulated ceramide metabolism is linked to numerous human diseases, including cancer (6, 7) . Consistent with this, many anticancer agents have been shown to modulate ceramide synthesis by regulating individual components of the de novo pathway. For example, daunorubicin stimulates both de novo ceramide synthesis and sphingomyelin hydrolysis (8, 9) , camptothecin and fludarabine induce de novo ceramide production in various human cancer cells (10) , and etoposide enhances serine palmitoyltransferase in leukaemia cells (11) . Other cytotoxic drugs such as cytosine arabinoside (Ara-C) are able to activate neutral sphingomyelinase to generate ceramide in leukaemic cells (12) . In contrast to the actions of ceramide, sphingosine-1-phosphate (S1P), generated from ceramide hydrolysis and further phosphorylation of the resulting sphingosine, is known as a regulator of cell proliferation, inflammation, vasculogenesis and resistance to apoptotic cell death (13). Hence, the relative balance between ceramide and S1P has been proposed to influence the cell fate in response to cytotoxic stimuli.
Ceramidases are the enzymes that catalyze ceramide hydrolysis to release sphingosine and the corresponding fatty acid. According to their pH optima of activity, acid, neutral and alkaline ceramidases can be distinguished (14) . Among these ceramidases, acid ceramidase (aCDase), encoded by the ASAH1 gene, appears to play an important role in cancer progression. For instance, aCDase is upregulated in prostate cancer (15, 16) , conferring resistance of cancer cells to radiation (17) . Also, pharmacological inhibition of aCDase has been reported to completely prevent tumor growth of human colon cancer cells metastatic to the liver (18) and of prostate cancer xenografts (19) . In addition, downregulation of ASAH1 using specific siRNA reduced tumor growth in an in vivo model of hepatocellular carcinoma (20) .
Given that cytotoxic drugs regulate the metabolism of sphingolipids, we have explored the effects of DTIC in human A375 melanoma cells. This work shows for the first time that DTIC promotes aCDase degradation in lysosomes and the subsequent increase of intracellular ceramide levels in A375 cells. We also demonstrate that the modulation of aCDase expression affects the sensitivity of these tumor cells to DTIC treatment.
Experimental procedures
Cell lines-The human melanoma cell line A375 was obtained from the American Type Culture Collection. The A375 cell line that stably expresses the tetracycline repressor was obtained by transfection of the pcDNA6/TR vector with Lipofectamine 2000 (Invitrogen) and further selection with blasticidin (3 !g/ml). The cDNA of ASAH1 was subcloned into pcDNA5/TO and the sequence was verified. This vector was transfected into pcDNA6/TR A375 cells with Lipofectamine 2000 to obtain a new cell line (A375 ASAH1) that overexpresses ASAH1 under the control of a tetracycline/doxycycline responsive promoter. The antibiotic selection of this new cell line was performed with blasticidin (3 !g/ml) and hygromycin B (250 !g/ml). Ectopic expression of ASAH1 was induced with doxycycline at 1 !g/ml for 24 hours before treatment with DTIC. Cells were grown in a humidified 5% CO 2 atmosphere at 37ºC in DMEM medium containing Glutamax (Invitrogen). Sequences, vectors and siRNA tranfections-The cDNA coding for human ASAH1 was kindly provided by Dr. J. A. Medin (University of Toronto, Canada). The pcDNA6/TR and pcDNA5/TO plasmids belong to the T-REx TM system from Invitrogen. The pEGFP-LC3 vector was kindly provided by Dr. T. Yoshimori (Osaka University, Japan). siRNA against ASAH1, Atg7 and emerin (ON-TARGETplus SMART pool) were purchased from Dharmacon Thermo Scientific, and their transfection was performed at 10 nM using the Hi Perfect transfection reagent (Qiagen). Other reagents-Dacarbazine, doxycycline, Nacetylcysteine, pepstatin A, leupeptin, and monodansylcadaverine were supplied from Sigma, blasticidin and hygromycin B were from Invitrogen, CA074-Me was obtained from Enzo Life Sciences, zVAD-fmk was from Bachem, Ac-DEVD-AMC from Alexis and the MTT substrate was purchased from Euromedex. Enzyme substrates included Rbm14-12 (aCDase substrate) produced in our laboratories (21) , zRR-AMC, a cathepsin B fluorogenic substrate from Calbiochem, and 4-methylumbelliferyl-!-D-galactopyranoside (!-galactosidase substrate) obtained from Sigma. LC-MS analysis of sphingolipids-Sphingolipid extracts, fortified with internal standards (N-
N-dodecanoyl sphingosylphosphorylcholine and C17 Derythro-dihydrosphingosine-1-phosphate, 0.2 nmol each), were prepared as described (22) and analysed. The liquid chromatography-mass spectrometer (LC-MS) consisted of a Waters Aquity UPLC system connected to a Waters LCT Premier orthogonal accelerated time of flight mass spectrometer (Waters), operated in positive electrospray ionisation mode. Full scan spectra from 50 to 1500 Da were acquired and individual spectra were summed to produce data points each 0.2 s. Mass accuracy and reproducibility were maintained by using an independent reference spray via the LockSpray interference. The analytical column was a 100 mm " 2.1 mm id, 1.7 µm C8 Acquity UPLC BEH (Waters (21) . Each well contained a mixture of 74.5 !l of 25 mM sodium acetate buffer pH 4.5, 0.5 !l of a 4 mM Rbm14-12 substrate solution in ethanol, and a fixed amount of protein (20 !g) in a volume of 25 !l of a 0.2 M sucrose solution. The plate was incubated at 37ºC for 3 hours. Then, the enzymatic reaction was stopped by adding 50 !l of methanol and 100 !l of a 2.5 mg/ml NaIO 4 fresh solution in 100 mM glycine/NaOH buffer pH 10.6 in each well. The plate was protected from light for 2 hours and then the released fluorescence was quantified using a microplate fluorescence reader (" ex 360 nm, " em 446 nm). The amount of umbelliferone released was calculated from the fluorescence intensity by using calibration curves with umbelliferone, in the range from 0 to 3000 pmol.
The acid !-galactosidase activity was determined on the same cell lysates used for aCDase activity assay. This assay is based on a published fluorimetric method (24) with some modifications to adapt it to the 96-well plate format. Briefly, each well contained 20 !l of a 0.5 M sodium acetate buffer pH 4.5, 20 !l of a 20 mM EDTA solution, 40 !l of a 3 mM solution of 4-methylumbelliferyl-!-Dgalactopyranoside (final concentration of 1.2 mM), 10 !l of lysate and 10 !l of ultra pure water. After incubation at 37ºC for 30 min, the reaction was stopped by the addition of 100 !l of a 100 mM glycine/NaOH buffer pH 10.6. The fluorescence released was quantified using a microplate fluorescence reader (" ex 360 nm, " em 446 nm) as described above.
The cathepsin B activity was measured using the fluorogenic substrate zRR-AMC. The assay was carried out in 96-well plates. The incubation mixture of each well consisted in 95 !l of 0.4 M sodium acetate buffer pH 5.5 containing 30 !g of protein extracts prepared as described above, and 5 !l of a 1mM ethanolic solution of the substrate (final concentration 50 !M). After 1-hour incubation at 37ºC, the reaction was stopped by adding 100 !l of a 100 mM glycine/NaOH buffer pH 10.6. The amount of the released product was measured by fluorometry as described for the above assays.
! %!
Viability assay-Cell viability was determined by using the MTT assay (Euromedex), according to the manufacturer's instructions. Morphological analyses-A375 cells stably transfected with pEGFP-LC3 vector, were treated at different times with DTIC, then stained with monodansylcadaverine (50 !M) for 30 minutes and fixed with paraformaldehyde. Cells were examined under a fluorescence Leica DMR microscope equipped with a digital camera. Western Blot-Cells were washed with PBS and harvested. Cell pellets were resuspended in 0.1 ml of ice-cold PBS containing 10% glycerol, 1% Triton X-100, 1 mM NaVO 4 , 10 mM NaF, and a protease inhibitor cocktail (Roche), and further lysed by brief sonication. Samples were centrifuged at 10,000g for 10 min. Supernatants were collected and protein content was determined by the Bradford method (Bio-Rad). Proteins (30 to 50 !g of cell lysates) were separated on a 12.5% polyacrylamide gel. After transfer onto a nitrocellulose membrane (Millipore), immunoblotting was performed using a rabbit polyclonal anti-acid ceramidase antibody (a kind gift from Dr. K. Sandhoff, Bonn, Germany), rabbit anti-SphK1 (Sigma), rabbit anti-!-actin or rabbit anti-Atg7 (Cell Signalling). Density bands were quantified with ImageJ software (NIH Image). Quantitative RT-PCR-Non-confluent melanoma cells were harvested and RNA was extracted (RNeasy kit; Qiagen) according to the manufacturer's protocol and treated with DNase (Qiagen). RNA quality was assessed by automated gel electrophoresis (Experion; BioRad). RNA (2 µg) was reverse-transcribed (SuperScript II; Invitrogen) and used as a template for quantitative PCR. The reactions were done in duplicate on the StepOne instrument (Applied Biosystems) using SYBR Green PCR kit and primer assay (QuantiTect, Qiagen). Results were quantified using the system software. mRNA of TBP, TFRC, and $-actin were analyzed for normalization. Flow cytometry-Cells were washed and harvested by trypsinization. The analysis of LC3-EGFP fluorescence was assessed using a FACScan (BD Biosciences) cytometer as described previously (25) . The fluorescence intensity observed on FL1-H histogram inversely correlated with autophagic flux. Statistical analysis-Means and SEM were calculated in the different assays. Statistical significance between groups was assessed using the Student's t test. Differences were considered significant at * p < 0.05, ** p < 0.01, and *** p < 0.001.
RESULTS

Dacarbazine treatment of melanoma cells increases ceramide levels.
We first investigated the effects of DTIC treatment on the cellular levels of sphingolipids. To do this, A375 melanoma cells were treated with DTIC at 100 !g/ml for 48h, the concentration corresponding to its IC 50 in vitro (see supplementary table) . Mass spectrometry analysis of the lipidic extracts revealed an increase of ceramide levels, especially those of sixteen and eighteen-carbon chain length (about 1.6 and 1.4 fold, respectively) (Figs. 1A and B) . This is particularly relevant in the case of C16:0 ceramide since it is one of the major ceramide species in mammalian cells 1 . Also, we found that sphingosine and S1P levels were reduced by 50% and 75%, respectively (Fig. 1C) . Whereas glucosylceramide species were slightly increased, about 1.3 fold, sphingomyelin levels remained unaltered (data not shown). These observations on the sphingolipid profile focused our attention to ceramidases, since these degrading enzymes are responsible for the catabolism of ceramides to sphingosine.
Dacarbazine elicits acid ceramidase degradation. We centered our efforts on the study of aCDase, since several studies have connected this enzyme to cancer promotion and resistance to therapy, particularly of prostate cancer (15) (16) (17) . Likewise, a bioinformatic approach has found aCDase to be among the most important marker genes for melanoma (26) . These precedents and the above results of mass spectrometry led us to explore a possible relationship between this enzyme and the sensitivity of A375 melanoma cells to DTIC.
Interestingly, time-course experiments revealed a time-dependent decrease of aCDase activity after treatment with DTIC. After 48 hours of treatment, cells lost about 80% of aCDase basal levels ( Fig. 2A) . Cell viability was also reduced with time after treatment, being significantly affected from 16 hours onwards, when aCDase activity was reduced by 50% (Fig.  2B) . Also, the degradation of aCDase activity showed to be dose-dependent with a loss of more than 50% already at a 25 !g/ml concentration (Fig. 2C) . However, under the same conditions, lysosomal !-galactosidase activity was not decreased, meaning that the integrity of ! &! lysosomes was not compromised. Western blot experiments revealed a lower aCDase protein content in cells treated with DTIC 2 , whereas levels of sphingosine kinase 1 (SphK1) remained unchanged (Fig. 2D) . However, levels of ASAH1 transcripts after treatment remained unchanged (data not shown), thus pointing to a posttranscriptional degradation of aCDase. Of note, aCDase activity was not decreased in A375 cells treated with cytotoxic concentrations of cisplatin (80 !M, data not shown), meaning that aCDase degradation is not a common response to cytotoxics.
In order to investigate the mechanism responsible for aCDase degradation, A375 cells were preincubated with protease inhibitors, including the cysteine and serine protease inhibitor leupeptin and the aspartyl protease inhibitor pepstatin A. As a result, we observed that only leupeptin was able to protect cells from aCDase degradation elicited by low doses of DTIC (Fig. 3A) . Cathepsin B is a lysosomal cysteine protease that has been shown to be implicated in aCDase degradation after treatment with desipramine (27) . Thus, this enzyme was tested as a possible cause for aCDase degradation. Preincubation of A375 melanoma cells with the cathepsin B inhibitor CA074-Me resulted in a near total protection of aCDase activity from DTIC-induced degradation (Fig.  3B) . Next, we wanted to explore whether aCDase degradation was the consequence of caspase activation, as the activity of effector caspases measured using the fluorogenic substrate Ac-DEVD-AMC increased at 48 hours after DTIC treatment (data not shown). To check this, A375 melanoma cells were preincubated with z-VAD-fmk, a broad caspase inhibitor, and then treated with DTIC. We observed that aCDase activity was not protected from degradation, meaning that caspases were not involved in this activity loss (Fig. 3C) .
Dacarbazine-induced generation of ROS occurs prior to acid ceramidase degradation. Cellular metabolism of DTIC is believed to lead to the production of ROS in the cytoplasm giving H 2 O 2 , that diffuses to the lysosomes causing cell damage (28) . Also, it has been reported that temozolomide is able to induce autophagy in cells (29) , although the relationship between production of ROS, lysosomal damage and autophagy has not been clarified yet for DTIC.
To investigate the role of ROS in aCDase degradation, possibly through cathepsin B activation, we preincubated A375 cells with Nacetylcysteine (NAC), a precursor of glutathione, a major intracellular antioxidant. As shown in Fig. 4A , NAC protected A375 cells from aCDase degradation, triggered by low doses of DTIC (from 5 to 25 !g/ml). As a consequence, after DTIC treatment at 10 !g/ml, the increase of ceramide levels was only 20% to that of cells not preincubated with NAC (data not shown). Regarding cathepsin B activity, a considerable increase of its activity was observed after DTIC treatment, which peaked at 24 hours, and was completely abrogated in the presence of NAC (Fig. 4B) . These findings suggest that the production of ROS after DTIC treatment leads to aCDase degradation, probably through cathepsin B activation. Cell death after treatment with low doses of DTIC was also attenuated in the presence of NAC (Fig. 4C) .
Acid ceramidase degradation is involved in dacarbazine-induced autophagy of melanoma cells. Next, DTIC-induced autophagy of A375 melanoma cells was investigated. It was assessed by flow cytometry of A375 cells stably transfected with pEGFP-LC3. This method is based on the fact that the EGFP molecule is sensitive to low pH, making its fluorescence disappear when LC3-EGFP is delivered into lysosomes, i.e., when autophagolysosomes are formed (25) . Using this method we observed that while A375 cells lost 10% of fluorescence intensity under DTIC treatment, preincubation with NAC totally prevented the fluorescence loss (data not shown). Thus, protection by NAC from DTIC-induced autophagy is mediated by ROS formation. However, it was still unclear whether the DTIC-induced loss of aCDase activity was involved in the autophagy and the ensuing cell death observed.
To further explore these mechanisms, the onset of autophagy was assessed by EGFP-LC3 dot formation and monodansylcadaverine staining (30) . When A375 melanoma cells were treated with DTIC (100 !g/ml), we observed that the punctuate structures, corresponding to autophagosomes and autophagolysosomes, appeared between 8 and 16 hours (Fig. 5A) . Remarkably, occurrence of the autophagic features was concomitant to the decrease of aCDase activity after DTIC treatment ( Fig. 2A) . Also, C16:0 and C18:0 ceramide levels, assessed by mass spectrometry, started to increase between 8 and 16 hours after treatment (Fig. 5B) . These observations suggest that there is a temporal relationship between aCDase ! '! degradation, ceramide accumulation and the onset of autophagy. To investigate whether aCDase degradation was a consequence of the autophagic process triggered by DTIC, A375 melanoma cells were transfected with a siRNA against Atg7, in order to inhibit autophagy (31) . Despite efficient Atg7 silencing, aCDase degradation was still taking place, meaning that aCDase degradation likely occurs upstream autophagy induced by DTIC (Fig. 5C) .
Silencing of acid ceramidase sensitizes while overexpression renders A375 melanoma cells more resistant to dacarbazine. To further investigate the implication of aCDase on cell survival after DTIC treatment, aCDase expression was modulated. For ASAH1 downregulation, melanoma A375 cells were transfected with specific siRNA against ASAH1. After treatment with siRNA at a concentration of 10 nM, ASAH1 expression, assessed by quantitative RT-PCR, was reduced to 15% ( Fig  6A) . aCDase activity was also dramatically reduced ( Fig 6B) . Under these conditions, we found a small (10%), but not statistically significant increase in total ceramides. However, when we explored the values of the molecular ceramide species, an increase was observed for C16 and C18 species (22% and 26% increase, data not shown) 3 . These little changes are probably due to compensation by other ceramide metabolizing enzymes and/or residual aCDase activity. Nevertheless, under treatment with DTIC, the combination of ASAH1 silencing and aCDase degradation made aCDase activity almost undetectable (Fig. 6B ). This was translated into a 20% increase of ceramide levels (especially those of C16, C18, C22 and C24:1 ceramides with increases between 30 and 40%), and decreased levels of sphingosine and S1P (about 40% and 60%, respectively), compared to those of DTIC-treated cells transfected with control siRNA (see Fig. 6C ). Under conditions of downregulation of ASAH1, cell viability was reduced by about 20%. Combination of ASAH1 downregulation and DTIC treatment at doses ranging from 5 to 200 !g/ml resulted in a significantly increased sensitivity of A375 cells to DTIC (Fig. 6D) . Viability of A375 cells was reduced by 45 to 65% of that of cells transfected with control siRNA. As a reciprocal approach, ASAH1 was overexpressed in A375 melanoma cells. The TRex inducible expression system (Invitrogen) was used to establish the A375 ASAH1 cell line, which after addition of doxycycline at 1 !g/ml, ectopically expressed aCDase. Western blot analysis and aCDase activity assays indeed attested the effectiveness of this system (Fig.  7A) . Ceramide levels in A375 ASAH1 cells were considerably decreased (by 40-50%), especially those of C16, C22 and C24:1 ceramides, in DTIC-treated cells after induction as compared to non-induced cells (Fig. 7B) . This was accompanied by a significant (50%) increase in sphingosine levels, but no changes in the S1P content were detected in DTIC-treated A375 ASAH1 induced cells compared to the noninduced (Fig. 7B) .
When induced A375 ASAH1 cells were treated with DTIC at different doses, almost no loss of aCDase activity was detected (Fig. 7C) . Indeed, whereas induced cells conserved more than 80% of aCDase activity, non-induced cells exhibited less than 20% of the initial activity.
Next, cell viability after DTIC treatment in induced and non-induced A375 ASAH1 cells was determined. Cells that overexpressed aCDase were more resistant to DTIC treatment, most significantly at doses below 50 !g/ml (Fig.  7D) . When the effects of another cytotoxic drug, cisplatin, were explored, no difference was observed between induced and non-induced cells (See Supplementary Fig. S1 ), meaning that protection of A375 melanoma cells by overexpression of aCDase may be restricted to dacarbazine. The viability results obtained both by downregulation and overexpression experiments suggest that aCDase activity modulates A375 cell sensitivity to DTIC likely through changes in the intracellular levels of ceramide. In support to this idea, another human melanoma cell line, UACC257, proved to be very resistant to DTIC (see Supplementary table) . This cell line exhibited a 10-fold higher aCDase activity than that of A375 ( Supplementary Fig. S2 ), suggesting a direct correlation between aCDase activity and resistance to DTIC. Such a correlation was observed in other human melanoma cell lines between ASAH1 mRNA levels, acid ceramidase content and enzyme activity, and sensitivity to DTIC ( Supplementary  Fig. S2) .
DISCUSSION
The present work identifies aCDase as a novel target for DTIC. We demonstrate for the first time that DTIC, the most active agent for treating metastatic melanoma, triggers a ROS-
cathepsin-mediated proteolytic degradation of aCDase in a time and dosedependent manner. This is followed by ceramide accumulation and ensuing cell death with autophagic features. Genetic manipulation of aCDase expression showed that the expression/activity of this lipid hydrolase is able to modulate the response of melanoma cells to DTIC.
Our results show that aCDase degradation is probably carried out by cathepsin B, as its specific inhibition with CA074-Me protects cells from aCDase activity loss. This finding is reminiscent of the involvement of cathepsins B and L in the aCDase degradation induced by chemical treatments, such as desipramine, chloroquine or chlorpromazine (27) .
It is known that temozolomide and DTIC are DNA-alkylating agents. Recently, it has been proposed that they can also be metabolized in the cytosol to MTIC (5-(3-monomethyl-1-triazeno)-imidazole-4-carboxamide), to further produce ROS that diffuse to lysosomes (28) . Blocking these species by using NAC in DTIC-treated A375 cells conferred protection from increase in cathepsin B activity, aCDase degradation, ceramide accumulation, cell death and autophagy. These results strongly suggest that the production of ROS after DTIC treatment is a causal event in aCDase degradation, probably through cathepsin B activation. Furthermore, ROS would be also implicated in cell death and autophagy. This is in accordance with a previous work demonstrating that ROS participate in TNF#-induced stimulation of autophagy (32) .
Autophagy encompasses processes by which cytoplasmic materials reach lysosomes for degradation. Under physiological conditions, autophagy plays a role on cell maintenance and adaptation under numerous stimuli (33, 34) . Cellular autophagic activity is normally low under basal conditions, but some cancer cells, due to their localization, often in hypoxic or nutrient-deprived environments, exhibit high rates of autophagy. For instance, A375 melanoma cells display elevated basal levels of autophagy, which made it difficult to measure little changes in autophagy induced by DTIC treatment. Thus, we could not use Western blot analysis for reliable LC3-II detection and quantification. Instead of this technique, we could assess autophagy by flow cytometry of cells stably expressing LC3-EGFP. Besides its self-defense role, autophagy can also promote a form of cell death, called programmed cell death II, presumably by excessive activation of autophagy to a point from which recovery of the cell is unattainable (35) . In cancer therapy, activation of autophagy in apoptosis-resistant tumors could provide a way to induce cell death and prevent tumor growth. In this sense, cytotoxic drugs like arsenic trioxide, Imitanib, rapamycin among others can induce autophagic death of cancer cells (35) .
In our A375 cell model, DTIC-induced aCDase degradation was accompanied by accumulation of ceramides (mainly C16 and C18 species) and decreased sphingosine and S1P levels. Besides its pro-apoptotic properties, ceramide has also been described as an inducer of autophagy (36, 37) . Consistent with this, our results show a temporal relationship between the degradation of aCDase, the increase of ceramide levels, and the onset of autophagic features after DTIC treatment, suggesting that, in our model, the accumulation of ceramide resulting from aCDase degradation could be involved in the induction of autophagy 4 .
Regarding a possible induction of apoptosis after DTIC treatment, we started to detect cleavage of caspase 3 after 48 hours of treatment (data not shown), meaning that apoptosis is not an early event in DTIC-treated A375 melanoma cells. This is in agreement with a previous report on temozolomide-treated malignant glioma cells (29) . One possibility is that autophagy contributes to the induction of apoptosis as a result of a cross-talk between these two types of programed cell death (31) . This is exemplified in Djavaheri-Mergny et al.'s work (38) , where activation of autophagy by TNF# was required for induction of apoptosis and cell death.
Our findings also show that the modulation of ASAH1 expression can regulate the sensitivity of A375 melanoma cells to DTIC. ASAH1 downregulation sensitized cells to the treatment, probably through increased levels of ceramide. Sensitization of cells by ASAH1 downregulation (20) or by enzymatic inhibition (19) has already been reported in other cancer models. Interestingly, downregulation of other ceramidases such as neutral (ASAH2) or alkaline ceramidase 2 (ASAH3L) did not recapitulate the sensitizing effects of ASAH1 silencing (only ASAH3L silencing slightly increased the sensitivity of cells to DTIC, see Supplementary  Fig. S3 ).
Conversely, we report that aCDase ! )! overexpression can partially protect A375 cells from cell death at low doses of DTIC. A possible explanation for this limited effect is that under high doses of DTIC, other mechanisms not related to ceramide metabolism are triggered (e.g. DNA alkylation). These results are in accordance with a previous study showing that overexpression of aCDase in prostate cells confers resistance to several cytotoxic drugs (16) . The fact that the protection from cell death observed after overexpressing aCDase only takes place under DTIC but not cisplatin treatment, suggests that there is a specific mechanism of DTIC involving aCDase (as a matter of fact, cisplatin did not induce a decrease of aCDase activity).
Another proof of aCDase involvement in the resistance to DTIC is the direct correlation observed between ASAH1 mRNA levels, aCDase activity and the sensitivity to DTIC in several human melanoma cell lines.
Of note, inducible ASAH2 overexpression was not associated with significant changes in cell viability after treatment with DTIC ( Supplementary Fig. S3B ) as well as other cytotoxics, like cisplatin or etoposide (data not shown). Together with the absence of effects of ASAH2 downregulation, this suggests that neutral ceramidase is not involved in the response of A375 to DTIC, probably due to the different localization of the accumulated ceramide.
In conclusion, the present data strongly indicate that metabolism of ceramide by aCDase action is involved in the sensitivity of melanoma cells to DTIC. Taken together, this work further strengthens the importance of aCDase as a key factor in melanoma progression (26, 39) . It also suggests that aCDase downregulation, in combination with DTIC, may be a promising strategy for improved treatment of metastatic melanoma.
!"+! 1 A significant increase in total ceramide levels was observed after quantification using the DAG kinase method (984 ± 161 pmol/mg protein in DTIC-treated cells versus 500 ± 144 pmol/mg protein in control cells; n=7; p<0.001). 2 Any Mr species smaller than 13 kDa were not observed, possibly due to the lack of recognition of such fragments by the antibody used. 3 The changes in ceramide levels were accompanied by a significant decrease in sphingosine content (Fig. 6C ) and a significant increase in glucosylceramide level (data not shown). 4 The decreased levels of sphingosine and S1P observed under DTIC treatment may suggest that the increased ceramide levels are not the only cause of the cell death observed. The same conclusion could apply for the decreased cell viability upon ASAH1 silencing. However, in cells that, DTIC failed to elevate ceramide, their sphingosine level remained high, but that of S1P still decreased. Thus, the resistance of the aCDase-overexpressing cells is likely not due to an effect on S1P but rather to a decrease of ceramide content. Fig. 1 . Dacarbazine-induced changes in intracellular ceramide concentrations. A375 melanoma cell lines were incubated for 48 hours in the presence or absence of DTIC (100 !g/ml). Cellular lipids were extracted and sphingolipid concentrations determined by LC-MS. Data represents the levels in pmol/10^6 cells of individual ceramide species (A); total ceramide species (B) and sphingosine (So) and sphingosine-1-phosphate (S1P) (C). Data are the means ± SEM of five independent determinations. Fig. 2 . Dacarbazine-induced loss of acid ceramidase activity. A, aCDase activity in A375 melanoma cells treated with DTIC (100 !g/ml) for the indicated times (mean ± SEM of three independent experiments). B, Time course of cell viability loss in A375 cells treated with 100 !g/ml DTIC (mean ± SEM of two independent experiments performed in sextuplicate). C, Dose dependency of decrease in aCDase activity (filled squares) in A375 cells incubated for 48 hours with the indicated concentrations of DTIC (data are from a representative experiment performed in duplicate). In the same cell lysates, the activity of acid !-galactosidase (open squares) was determined. D, Western blot analysis of aCDase and Sphk1 in A375 cells treated with DTIC (100 !g/ml) for 48 hours. ) . B, Effect of the cathepsin B inhibitor CA074-Me on the loss of aCDase activity. Cells were preincubated for 2 hours with CA074-Me (5 !M) and then treated for 24 hours with or without DTIC (25 !g/ml). C, Effect of the broad caspase inhibitor zVAD-fmk on aCDase activity. Cells were preincubated with zVAD-fmk (20 !M) or DMSO for 2 hours, then treated for 48 hours with or without DTIC (25 !g/ml). Data are the means ± SEM of three independent experiments. Fig. 4 . Effect of N-acetylcysteine on acid ceramidase activity (A), cathepsin B activity (B) and cell viability (C) in dacarbazine-treated melanoma cells. A and C, A375 cells were preincubated for 2 hours in the presence or absence of NAC (10 mM) and then treated for 48 hours with the indicated concentration of DTIC. Data are means ± SEM of three independent experiments performed in triplicate. B, Cathepsin B activity was determined in cells preincubated or not for 2 hours with 10 mM NAC and then treated for the indicated times with DTIC (10 !g/ml). Enzyme activity is expressed in percentage of that measured in cells preincubated with or without NAC for only 2 hours, but not treated by DTIC (mean ± SEM of three independent experiments). Western blot analysis were performed (data are means ± SEM of three independent experiments). B, aCDase activity of cells transfected with siRNA against aCDase or emerin for 24 hours, then treated with or without DTIC for 48 hours (data are representative of two independent experiments performed in duplicate). C, A375 cells were transfected with siRNA against ASAH1 or a control siRNA and 24 hours later, cells were treated or not with DTIC (100 !g/ml) for 48 hours. Lipids were extracted and levels of total ceramides, sphingosine (So) and S1P were quantified by LC-MS. Data are means ± SEM of three independent experiments performed in duplicate. D, Cell viability of A375 cells transfected with aCDase or emerin siRNA for 24 hours, then treated with the indicated concentrations of DTIC for 48 hours (mean ± SEM of three independent experiments performed in triplicate). Fig. 7 . Effects of aCDase overexpression in A375 melanoma cells. A, A375 ASAH1 cells were treated or not with doxycycline (DOX, 1 !g/ml) for 24 hours. Then, aCDase activity measurement and Western Blot analysis were performed (data are representative of more than five experiments). B, A375 ASAH1 cells were induced or not with doxycycline for 24 hours, then treated or not with DTIC (10 !g/ml) for 48 hours. Lipids were extracted and levels of total ceramides, sphingosine (So) and S1P were quantified by LC-MS. Data are means ± SEM of three independent experiments performed in duplicate. C, aCDase activity was measured in A375 cells preincubated for 24 hours and then treated for 48 hours with the indicated concentrations of DTIC (mean ± SEM of two independent experiments performed in duplicate). D, Cell viability was measured in 24-hour induced and non-induced cells treated for 48 hours with the indicated concentrations of DTIC. Results are means ± SEM of three independent experiments performed in triplicate.
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